MARKET

DTIL

DTIL

Precision Biosciences
NASDAQ
7.27
-0.84
-10.36%
After Hours: 7.22 -0.05 -0.69% 19:59 05/15 EDT
OPEN
8.01
PREV CLOSE
8.11
HIGH
8.06
LOW
7.25
VOLUME
239.66K
TURNOVER
--
52 WEEK HIGH
8.82
52 WEEK LOW
3.530
MARKET CAP
187.59M
P/E (TTM)
-1.9825
1D
5D
1M
3M
1Y
5Y
1D
Precision BioSciences presents new preclinical data on Pbgene-DMD program
TipRanks · 2d ago
Precision BioSciences Announces New Preclinical Data From PBGENE-DMD Program In Oral Presentation At ASGCT 2026 Annual Meeting
Benzinga · 2d ago
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Barchart · 2d ago
Weekly Report: what happened at DTIL last week (0504-0508)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Precision BioSciences (DTIL)
TipRanks · 05/07 05:51
Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT)
TipRanks · 05/06 16:50
Precision BioSciences GAAP EPS of -$0.75 misses by $0.09, revenue of $10.84M beats by $6.79M
Seeking Alpha · 05/05 11:52
Precision BioSciences sees cash runway through 2028
TipRanks · 05/05 11:37
More
About DTIL
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.

Webull offers Precision BioSciences Inc stock information, including NASDAQ: DTIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DTIL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DTIL stock methods without spending real money on the virtual paper trading platform.